Vaccinex plans to delist its Common Stock from Nasdaq after suspension since Dec 2024. Company uses SEMA4D blockage to treat neurodegenerative diseases.
On March 07, 2025, Vaccinex, Inc. (OTC: VCNX) revealed its choice to delist the Company's common stock from the Nasdaq Stock Market. The clinical-stage biotechnology company has been focused on a novel approach to treating neurodegenerative diseases by targeting astrogliosis and neuroinflammation via SEMA4D inhibition. Nasdaq halted trading of Vaccinex's common stock on December 18, 2024.